Hester Biosciences posts strong Q3 profit surge as poultry business powers growth
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Subscribe To Our Newsletter & Stay Updated